List of Excipients in Branded Drug XULTOPHY 100/3.6

« Back to Dashboard

Xultophy 100/3.6 Excipient Strategy and Commercial Opportunities

Last updated: October 30, 2026

Xultophy 100/3.6 is a fixed-ratio injectable combination of insulin degludec and liraglutide supplied in a prefilled FlexTouch pen. Its excipient system is designed to preserve two chemically different peptide actives in one aqueous formulation while supporting subcutaneous delivery, dose accuracy, antimicrobial protection, and insulin degludec’s zinc-dependent multi-hexamer structure.

The strongest commercial opportunities are in high-purity excipients, sterile formulation and filling, analytical comparability, device-compatible packaging, and alternative fixed-ratio combination products. Direct excipient substitution is commercially difficult because small changes in pH, zinc, preservative concentration, or buffer capacity can affect peptide stability, aggregation, potency, injection tolerability, and delivered dose.

What is the composition of Xultophy 100/3.6?

Xultophy contains 100 units/mL of insulin degludec and 3.6 mg/mL of liraglutide. The product is administered once daily using a multidose prefilled pen. The maximum labeled dose is 50 dose steps, corresponding to 50 units of insulin degludec and 1.8 mg of liraglutide.[1]

Component	Function in the formulation
Insulin degludec	Basal insulin active ingredient
Liraglutide	GLP-1 receptor agonist active ingredient
Glycerol	Tonicity and osmolality control
Phenol	Antimicrobial preservative and stabilizer
Metacresol	Antimicrobial preservative and protein-stabilizing excipient
Zinc acetate	Supports insulin degludec self-association and depot formation
Sodium acetate	Buffering and pH control
Hydrochloric acid and sodium hydroxide	pH adjustment
Water for injection	Vehicle

The U.S. prescribing information specifies an approximately neutral-to-alkaline formulation with a target pH of about 8.15.[1] The formulation does not use a conventional surfactant such as polysorbate 20 or polysorbate 80 in the U.S. label composition.

Why does Xultophy use both phenol and metacresol?

Phenol and metacresol provide antimicrobial protection for a multidose injectable product. They also interact with insulin formulations and can influence the reversible association state of insulin molecules.

The dual-preservative system is a formulation constraint rather than a simple preservative choice. Reducing either component can alter microbial protection, protein conformation, adsorption behavior, and injection-site tolerability. Increasing preservative concentration can create local tolerability concerns and may affect peptide stability.

Commercial suppliers must therefore deliver narrow assay ranges, low bioburden, low endotoxin, consistent impurity profiles, and reliable supply under injectable-grade quality systems.

How do the excipients stabilize insulin degludec and liraglutide?

Xultophy combines two peptide drugs with different formulation requirements.

Insulin degludec forms soluble multi-hexamers after subcutaneous injection. Zinc is central to this assembly process. After injection, the multi-hexamer structure gradually releases insulin degludec monomers into circulation, supporting its ultra-long basal activity.[2]

Liraglutide is an acylated GLP-1 analogue. Its fatty-acid side chain increases albumin binding and extends systemic exposure. The formulation must maintain liraglutide solubility and limit chemical and physical degradation during storage and repeated pen use.[3]

The excipient system has four technical priorities:

1. Maintain insulin degludec association behavior.
2. Preserve liraglutide solubility and conformational stability.
3. Limit aggregation, adsorption, oxidation, and deamidation.
4. Maintain antimicrobial protection after repeated needle puncture.

Which excipients are most strategically important?

Zinc acetate is the most product-specific excipient because it is linked directly to insulin degludec assembly. A replacement zinc salt or altered zinc concentration could change the product’s self-association profile and pharmacokinetics.

Phenol and metacresol are commercially important because they combine preservative activity with protein-interaction effects. Glycerol is less differentiated but remains important for tonicity and injection performance. Sodium acetate supports pH control but is less likely to create a unique commercial barrier than zinc or the preservatives.

The commercial ranking is therefore:

Excipient category	Technical importance	Substitution difficulty	Commercial opportunity
Zinc salt	High	High	High
Phenol and metacresol	High	Medium-high	High
Buffer system	Medium-high	Medium	Medium
Glycerol	Medium	Low-medium	Medium
Water for injection	Essential	Low	Low
pH adjusters	Medium	Low	Medium

What formulation patents protect Xultophy?

Xultophy is protected primarily through the active-ingredient combination, fixed-ratio dosing, formulation, manufacturing processes, device presentation, and method-of-use claims. Excipient suppliers should not assume that a compendial excipient is free of product-level intellectual-property risk.

An excipient itself is usually not the principal Orange Book barrier. Risk can arise from:

• A claimed concentration range for zinc, phenol, metacresol, or buffer.
• A formulation claim covering both insulin degludec and liraglutide.
• A stability or manufacturing process that relies on a defined excipient sequence.
• A prefilled-pen or cartridge configuration.
• A method-of-use claim covering titration or combination therapy.

The FDA Orange Book identifies drug-product patent and exclusivity information, but it does not provide a complete freedom-to-operate analysis for every excipient supplier, formulation process, or manufacturing route.[4] A supplier can sell a pharmacopeial excipient without practicing a product patent, but a finished-product developer may still face formulation or process claims.

What is the FDA regulatory status of Xultophy?

Xultophy was approved in the United States in November 2016 under NDA 208583.[1] It is a prescription fixed-ratio combination product for adults with type 2 diabetes inadequately controlled on basal insulin or liraglutide, together with diet and exercise.

The FDA-approved product is a combination drug-device presentation. The FlexTouch pen delivers dose steps containing one unit of insulin degludec and 0.036 mg of liraglutide per step.[1]

The principal regulatory implications for excipient strategy are:

• Excipients are part of the approved finished-product control strategy.
• A meaningful excipient change requires comparability data.
• A change affecting peptide aggregation, preservative effectiveness, pH, osmolality, or delivered dose may require expanded stability and clinical bridging.
• The delivery device and cartridge are part of the product performance system.
• A new fixed-ratio formulation would likely require a new regulatory submission rather than a straightforward generic substitution.

Can a generic or biosimilar replace Xultophy?

A conventional small-molecule ANDA pathway is not a practical assumption for Xultophy. The product contains two peptide actives, a defined fixed ratio, and a proprietary delivery presentation. Insulin products and GLP-1 analogues also have complex analytical and clinical comparability requirements.

A follow-on product could potentially use a 505(b)(2) strategy, a separate combination-product pathway, or another regulatory route depending on the legal status of the actives, the reference product, and the proposed formulation. A biosimilar designation for the complete Xultophy combination is not automatic because the product is a two-active fixed-ratio combination with a device-dependent dosing system.

For excipient companies, this creates two opportunities:

1. Support a follow-on developer with a formulation that uses the same excipient architecture.
2. Develop a differentiated combination product with a new ratio, concentration, device, or dosing profile.

The second route offers greater freedom but also greater clinical and regulatory expense.

What commercial opportunities exist in Xultophy excipients?

High-purity zinc systems

Zinc acetate and related zinc raw materials have the clearest technical differentiation. Suppliers can compete on:

• Trace-metal control.
• Low endotoxin and bioburden.
• Lot-to-lot concentration control.
• Compatibility with insulin degludec multi-hexamer formation.
• Global injectable-grade documentation.
• Supply continuity and dual sourcing.

The value proposition is strongest when a supplier provides formulation-grade material plus analytical support for particle formation, association state, potency, and stability.

Preservative systems

Phenol and metacresol suppliers can compete through consistent impurity profiles, low residual solvents, low color, low endotoxin, and validated sterilization or filtration compatibility.

A supplier that can provide a qualified dual-preservative package may reduce development time for combination insulin and GLP-1 products. The package must be assessed for preservative effectiveness after repeated dose withdrawal, not only at initial release.

Buffer and pH-control systems

Sodium acetate is a relatively accessible excipient, but buffer strategy is commercially relevant for new formulations. Developers may evaluate acetate, phosphate, citrate, or other systems to improve stability or reduce injection discomfort.

A buffer change must be tested against:

• Liraglutide aggregation.
• Insulin degludec association.
• Zinc precipitation.
• Container closure interaction.
• Delivered dose uniformity.
• Storage stability across temperature excursions.

Sterile fill-finish and cartridge services

Xultophy-type products require expertise in low-volume, multidose, peptide-containing sterile products. Contract manufacturers can capture value through:

• Low-shear formulation and filling.
• Cartridge filling for pen systems.
• Preservative effectiveness testing.
• Subvisible-particle control.
• Silicone-oil and tungsten-risk management.
• Device compatibility and dose-delivery testing.
• Stability programs for in-use multidose conditions.

The commercial barrier is higher than for ordinary aqueous injectables because peptide aggregation and device interaction can develop during filling, storage, transport, and repeated use.

Analytical comparability

Analytical laboratories can support developers with orthogonal methods for:

• Insulin degludec identity and potency.
• Liraglutide identity and potency.
• High-molecular-weight species.
• Aggregation and subvisible particles.
• Free and associated insulin species.
• Zinc content and distribution.
• Preservative concentration.
• pH, osmolality, and extractables.
• Delivered-dose uniformity.

A strong analytical package can be more valuable than a low-cost excipient because it reduces formulation iteration and regulatory risk.

How does Xultophy compare with Soliqua?

Xultophy competes most directly with Soliqua 100/33, another fixed-ratio basal insulin and GLP-1 receptor agonist product. Xultophy combines insulin degludec with liraglutide, while Soliqua combines insulin glargine with lixisenatide.[5]

Attribute	Xultophy 100/3.6	Soliqua 100/33
Basal insulin	Insulin degludec	Insulin glargine
GLP-1 agonist	Liraglutide	Lixisenatide
Product form	Prefilled pen	Prefilled pen
Key formulation consideration	Zinc-dependent degludec association	Insulin glargine formulation and lixisenatide stability
Dose ratio	100 units/3.6 mg per mL	100 units/33 mcg per mL
Excipient strategy	Zinc, phenol, metacresol, acetate, glycerol	Product-specific buffer, preservative, and stabilizer system

The two products are not directly interchangeable from an excipient standpoint. A manufacturing platform optimized for insulin glargine may not transfer to insulin degludec because the association and release mechanisms differ.

What generic launch risks affect excipient suppliers?

Potential follow-on entrants face five major risks.

Formulation equivalence

Matching the label composition is not enough. The developer must demonstrate equivalent quality attributes and clinically relevant performance.

Device compatibility

Pen force, dose accuracy, dead volume, cartridge dimensions, extractables, and in-use stability can determine whether a formulation is commercially viable.

Preservative and tolerability balance

The preservative system must protect the multidose product without increasing local reactions or altering peptide behavior.

Manufacturing scale-up

A formulation that performs in laboratory vials may fail during high-speed filling because of shear, air-liquid interfaces, hold times, or mixing order.

Patent and regulatory timing

A follow-on product may face active formulation, process, device, or method-of-use patents even after older active-ingredient patents expire. Paragraph IV litigation risk depends on the current Orange Book listing and the claims asserted by the brand owner.[4]

How strong is the excipient-related patent estate?

The excipient-related estate is strongest where the excipient is linked to a functional product limitation. Zinc concentration, preservative combinations, pH ranges, fixed-ratio peptide formulations, and manufacturing conditions are more defensible than the mere use of glycerol or water for injection.

A practical strength assessment is:

Claim area	Relative patent strength
Specific fixed-ratio combination	High
Product-specific formulation range	High
Zinc-enabled insulin association	Medium-high
Preservative combination	Medium
General glycerol use	Low
Water and routine pH adjustment	Low
Pen and cartridge integration	Medium-high
Manufacturing sequence and hold conditions	Medium-high

The commercial implication is clear: an excipient supplier should avoid relying on commodity pricing alone. The most defensible position combines qualified material, formulation know-how, analytical methods, and regulatory documentation.

What is the outlook for excipient suppliers?

Xultophy creates a specialized but narrow market. The product’s volume is smaller than that of basal insulin products sold independently, yet its formulation complexity raises the value of qualified supply.

The best opportunities are:

1. Dual-source qualification for zinc and preservative materials.
2. Excipient packages for fixed-ratio insulin and GLP-1 combinations.
3. Cartridge and pen-compatible sterile filling.
4. Stability-indicating analytical methods.
5. Reformulation support for lower injection volume or improved tolerability.
6. Follow-on product development using a differentiated device or dosing ratio.
7. Manufacturing process control for peptide aggregation and particle reduction.

Commodity glycerol and acetate supply will face price pressure. High-purity zinc, preservative systems, analytical characterization, and sterile combination-product manufacturing offer stronger margins and higher switching costs.

Key Takeaways

• Xultophy 100/3.6 combines insulin degludec and liraglutide in a preserved aqueous formulation.
• Zinc acetate is the most technically differentiated excipient because it supports insulin degludec multi-hexamer formation.
• Phenol and metacresol are important for both antimicrobial protection and peptide formulation behavior.
• Xultophy’s excipient system is closely tied to the pen, cartridge, multidose use period, and delivered-dose performance.
• Direct excipient substitution is difficult and requires comparability, stability, preservative-effectiveness, and device data.
• The strongest commercial opportunities are high-purity zinc, preservative systems, sterile fill-finish, analytical testing, and formulation support for follow-on fixed-ratio products.
• Xultophy is not a straightforward conventional generic opportunity because it contains two peptide actives in a fixed-ratio combination-product presentation.
• Product-level formulation, process, device, and method-of-use patents can remain relevant even when individual active-ingredient patents expire.

FAQs

What is the main excipient barrier in Xultophy?

Zinc acetate is the principal technical barrier because zinc affects insulin degludec association and release behavior. Preservative concentration and pH are also critical.

Does Xultophy contain polysorbate?

The U.S. prescribing information lists glycerol, phenol, metacresol, zinc acetate, sodium acetate, water, and pH-adjusting agents. It does not list polysorbate as an excipient.[1]

Can Xultophy be reformulated with phosphate buffer?

A phosphate buffer may be technically possible for a new product, but it would require evaluation of zinc compatibility, peptide aggregation, pH stability, osmolality, and clinical comparability. It should not be treated as a routine substitution.

Which excipient has the highest supplier value?

Qualified zinc acetate and the phenol-metacresol preservative system have greater strategic value than commodity glycerol or acetate because they are more closely linked to product performance.

Is there biosimilar risk for Xultophy?

A direct biosimilar replacement is not automatic. A follow-on developer would need to address the two-active fixed-ratio formulation, analytical comparability, device performance, and the applicable FDA regulatory pathway.

References

1. U.S. Food and Drug Administration. (2016). Xultophy 100/3.6 (insulin degludec and liraglutide) injection prescribing information. Novo Nordisk.

2. Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P. O., Ribel, U., & Ploug, M. (2012). Design of insulin degludec, a long-acting basal insulin analog. Pharmaceutical Research, 29(8), 2104-2114.

3. Knudsen, L. B., & Lau, J. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10, 155.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (2016). Soliqua 100/33 (insulin glargine and lixisenatide) injection prescribing information. Sanofi-Aventis U.S. LLC.